MAP2K6 and cancer: The reduced expression of the MAP2K6 gene in the malignant sample group (group 2) and in the PTC samples group (group 4) compared to the group of normal and benign samples (group 1) suggests that this gene could serve as a diagnostic marker in malignant neoplasms.